SWX:ROG

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. More Details


Snowflake Analysis

Solid track record with excellent balance sheet and pays a dividend.


Similar Companies

Share Price & News

How has Roche Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ROG has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-3.8%

ROG

-3.6%

CH Pharmaceuticals

-1.9%

CH Market


1 Year Return

1.7%

ROG

-4.8%

CH Pharmaceuticals

-1.8%

CH Market

Return vs Industry: ROG exceeded the Swiss Pharmaceuticals industry which returned -5.1% over the past year.

Return vs Market: ROG exceeded the Swiss Market which returned -1.1% over the past year.


Shareholder returns

ROGIndustryMarket
7 Day-3.8%-3.6%-1.9%
30 Day-9.4%-7.8%-2.0%
90 Day-8.3%-5.9%-1.7%
1 Year4.9%1.7%-1.6%-4.8%1.6%-1.8%
3 Year44.3%30.6%30.7%11.9%15.5%3.3%
5 Year32.2%12.2%23.2%-1.1%31.3%9.3%

Price Volatility Vs. Market

How volatile is Roche Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Roche Holding undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ROG (CHF299.7) is trading below our estimate of fair value (CHF658.3)

Significantly Below Fair Value: ROG is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ROG is good value based on its PE Ratio (19.8x) compared to the XE Pharmaceuticals industry average (22.3x).

PE vs Market: ROG is good value based on its PE Ratio (19.8x) compared to the Swiss market (21.6x).


Price to Earnings Growth Ratio

PEG Ratio: ROG is poor value based on its PEG Ratio (2.9x)


Price to Book Ratio

PB vs Industry: ROG is overvalued based on its PB Ratio (8.1x) compared to the CH Pharmaceuticals industry average (3.1x).


Next Steps

Future Growth

How is Roche Holding forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

6.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ROG's forecast earnings growth (6.9% per year) is above the savings rate (-0.2%).

Earnings vs Market: ROG's earnings (6.9% per year) are forecast to grow slower than the Swiss market (11.9% per year).

High Growth Earnings: ROG's earnings are forecast to grow, but not significantly.

Revenue vs Market: ROG's revenue (3.1% per year) is forecast to grow slower than the Swiss market (4.5% per year).

High Growth Revenue: ROG's revenue (3.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ROG's Return on Equity is forecast to be high in 3 years time (36.2%)


Next Steps

Past Performance

How has Roche Holding performed over the past 5 years?

8.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ROG has high quality earnings.

Growing Profit Margin: ROG's current net profit margins (20.8%) are higher than last year (19.1%).


Past Earnings Growth Analysis

Earnings Trend: ROG's earnings have grown by 8.8% per year over the past 5 years.

Accelerating Growth: ROG's earnings growth over the past year (9.6%) exceeds its 5-year average (8.8% per year).

Earnings vs Industry: ROG earnings growth over the past year (9.6%) underperformed the Pharmaceuticals industry 13.1%.


Return on Equity

High ROE: ROG's Return on Equity (39.3%) is considered high.


Next Steps

Financial Health

How is Roche Holding's financial position?


Financial Position Analysis

Short Term Liabilities: ROG's short term assets (CHF27.7B) exceed its short term liabilities (CHF22.5B).

Long Term Liabilities: ROG's short term assets (CHF27.7B) exceed its long term liabilities (CHF23.1B).


Debt to Equity History and Analysis

Debt Level: ROG's debt to equity ratio (43.2%) is considered high.

Reducing Debt: ROG's debt to equity ratio has reduced from 124.4% to 43.2% over the past 5 years.

Debt Coverage: ROG's debt is well covered by operating cash flow (141.8%).

Interest Coverage: ROG's interest payments on its debt are well covered by EBIT (45.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Roche Holding current dividend yield, its reliability and sustainability?

3.00%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ROG's dividend (3%) is higher than the bottom 25% of dividend payers in the Swiss market (1.98%).

High Dividend: ROG's dividend (3%) is low compared to the top 25% of dividend payers in the Swiss market (3.78%).


Stability and Growth of Payments

Stable Dividend: ROG's dividends per share have been stable in the past 10 years.

Growing Dividend: ROG's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (59.4%), ROG's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: ROG's dividends in 3 years are forecast to be well covered by earnings (43.5% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Severin Schwan (53 yo)

12.58yrs

Tenure

CHF12,189,402

Compensation

Dr. Severin Schwan, Ph.D., has been Chief Executive Officer of Roche Holding AG and Roche Holdings, Inc. and Roche Molecular Systems Inc. since March 2008. Dr. Schwan has been Group Chief Executive Officer ...


CEO Compensation Analysis

Compensation vs Market: Severin's total compensation ($USD0.00) is below average for companies of similar size in the Swiss market ($USD6.43M).

Compensation vs Earnings: Severin's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Severin Schwan
CEO & Executive Director12.58yrsCHF12.19m0.027%
CHF 68.1m
Alan Hippe
Chief Financial & IT Officer9.5yrsCHF5.68m0.0032%
CHF 8.3m
Karl Mahler
Head of Investor Relationsno datano datano data
Urs Jaisli
Chief Compliance Officerno datano datano data
Claudia Böckstiegel
General Counsel0.75yrno datano data
Cristina Wilbur
Chief People Officer4.58yrsCHF3.72m0.00050%
CHF 1.3m
Nicolas Dunant
Head of Group Media Relationsno datano datano data
Ehab Yousef
Head of Middle East Sub-Region 1no datano datano data
Boris Zaitra
Head of Group M&Ano datano datano data
Lance Duan
Managing Director3.25yrsno datano data
William Pao
Head of Pharma Research & Early Development (pRED)2.75yrsno datano data
James H. Sabry
Global Head of Pharma Partnering2.17yrsno datano data

3.3yrs

Average Tenure

53yo

Average Age

Experienced Management: ROG's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Severin Schwan
CEO & Executive Director12.58yrsCHF12.19m0.027%
CHF 68.1m
Bernard Poussot
Non-Executive Independent Director5.75yrsCHF330.00k0.00012%
CHF 307.6k
André Hoffmann
Independent Vice Chairman14.75yrsno data3.61%
CHF 9.3b
Paul Bulcke
Non-Executive Independent Director9.58yrsCHF330.00k0.00047%
CHF 1.2m
Christoph Franz
Independent Chairman6.75yrsCHF5.75m0.0029%
CHF 7.4m
Patrick Frost
Independent Non Executive Director0.58yrno datano data
Richard Lifton
Non-Executive Independent Director5.75yrsCHF339.78k0%
CHF 0
Anita Hauser
Non-Executive Independent Director3.58yrsCHF330.00k0.00037%
CHF 948.4k
Julie Brown
Non-Executive Independent Director4.58yrsCHF360.00k0.000090%
CHF 230.7k
Claudia Dyckerhoff
Non-Executive Independent Director4.58yrsCHF360.00k0.00025%
CHF 640.8k
Johannes Clevers
Non-Executive Independent Director1.58yrsno datano data
Jo¨rg Duschmale´
Independent Non Executive Director0.58yrno datano data

5.2yrs

Average Tenure

59yo

Average Age

Experienced Board: ROG's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Roche Holding AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Roche Holding AG
  • Ticker: ROG
  • Exchange: SWX
  • Founded: 1896
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF256.312b
  • Shares outstanding: 854.64m
  • Website: https://www.roche.com

Number of Employees


Location

  • Roche Holding AG
  • Konzern Hauptsitz
  • Grenzacherstrasse 124
  • Basel
  • Basel-Stadt
  • 4070
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RHHV.FOTCPK (Pink Sheets LLC)YesNon-Voting Equity SecuritiesUSUSDJan 1992
RHHB.FOTCPK (Pink Sheets LLC)Bearer SharesUSUSDJan 1992
RHO5DB (Deutsche Boerse AG)YesNon-Voting Equity SecuritiesDEEURJan 1992
ROSWX (SIX Swiss Exchange)Bearer SharesCHCHFJan 1992
ROGSWX (SIX Swiss Exchange)YesNon-Voting Equity SecuritiesCHCHFJan 1992
RHODB (Deutsche Boerse AG)Bearer SharesDEEURJan 1992
0QOKLSE (London Stock Exchange)YesNon-Voting Equity SecuritiesGBCHFJan 1992
RHOXTRA (XETRA Trading Platform)Bearer SharesDEEURJan 1992
RHO5XTRA (XETRA Trading Platform)YesNon-Voting Equity SecuritiesDEEURJan 1992
ROG NBMV (Bolsa Mexicana de Valores)YesNon-Voting Equity SecuritiesMXMXNJan 1992
0QQ6LSE (London Stock Exchange)Bearer SharesGBCHFJan 1992
RHHB.YOTCPK (Pink Sheets LLC)SPN ADR EACH REP 0.125 GENUSUSUSDAug 1992
RHO6DB (Deutsche Boerse AG)SPN ADR EACH REP 0.125 GENUSDEEURAug 1992
0TDFLSE (London Stock Exchange)SPN ADR EACH REP 0.125 GENUSGBUSDAug 1992

Biography

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiova ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 21:49
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.